Cargando…

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity

BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in tumor cells and promotes tumor cell survival after radiation-induced DNA damage. Because the pathway may not be completely inhibited after blockade of PI3K itself, due to feedback through mammalian target of rapamycin (...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokas, Emmanouil, Yoshimura, Michio, Prevo, Remko, Higgins, Geoff, Hackl, Wolfgang, Maira, Sauveur-Michel, Bernhard, Eric J, McKenna, W Gillies, Muschel, Ruth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348043/
https://www.ncbi.nlm.nih.gov/pubmed/22452803
http://dx.doi.org/10.1186/1748-717X-7-48
_version_ 1782232359032061952
author Fokas, Emmanouil
Yoshimura, Michio
Prevo, Remko
Higgins, Geoff
Hackl, Wolfgang
Maira, Sauveur-Michel
Bernhard, Eric J
McKenna, W Gillies
Muschel, Ruth J
author_facet Fokas, Emmanouil
Yoshimura, Michio
Prevo, Remko
Higgins, Geoff
Hackl, Wolfgang
Maira, Sauveur-Michel
Bernhard, Eric J
McKenna, W Gillies
Muschel, Ruth J
author_sort Fokas, Emmanouil
collection PubMed
description BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in tumor cells and promotes tumor cell survival after radiation-induced DNA damage. Because the pathway may not be completely inhibited after blockade of PI3K itself, due to feedback through mammalian target of rapamycin (mTOR), more effective inhibition might be expected by targeting both PI3K and mTOR inhibition. MATERIALS AND METHODS: We investigated the effect of two dual PI3K/mTOR (both mTORC1 and mTORC2) inhibitors, NVP-BEZ235 and NVP-BGT226, on SQ20B laryngeal and FaDu hypopharyngeal cancer cells characterised by EGFR overexpression, on T24 bladder tumor cell lines with H-Ras mutation and on endothelial cells. Analysis of target protein phosphorylation, clonogenic survival, number of residual γH2AX foci, cell cycle and apoptosis after radiation was performed in both tumor and endothelial cells. In vitro angiogenesis assays were conducted as well. RESULTS: Both compounds effectively inhibited phosphorylation of Akt, mTOR and S6 target proteins and reduced clonogenic survival in irradiated tumor cells. Persistence of DNA damage, as evidenced by increased number of γH2AX foci, was detected after irradiation in the presence of PI3K/mTOR inhibition, together with enhanced G2 cell cycle delay. Treatment with one of the inhibitors, NVP-BEZ235, also resulted in decreased clonogenicity after irradiation of tumor cells under hypoxic conditions. In addition, NVP-BEZ235 blocked VEGF- and IR-induced Akt phosphorylation and increased radiation killing in human umbilical venous endothelial cells (HUVEC) and human dermal microvascular dermal cells (HDMVC). NVP-BEZ235 inhibited VEGF-induced cell migration and capillary tube formation in vitro and enhanced the antivascular effect of irradiation. Treatment with NVP-BEZ235 moderately increased apoptosis in SQ20B and HUVEC cells but not in FaDu cells, and increased necrosis in both tumor and endothelial all cells tumor. CONCLUSIONS: The results of this study demonstrate that PI3K/mTOR inhibitors can enhance radiation-induced killing in tumor and endothelial cells and may be of benefit when combined with radiotherapy.
format Online
Article
Text
id pubmed-3348043
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33480432012-05-09 NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity Fokas, Emmanouil Yoshimura, Michio Prevo, Remko Higgins, Geoff Hackl, Wolfgang Maira, Sauveur-Michel Bernhard, Eric J McKenna, W Gillies Muschel, Ruth J Radiat Oncol Research BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in tumor cells and promotes tumor cell survival after radiation-induced DNA damage. Because the pathway may not be completely inhibited after blockade of PI3K itself, due to feedback through mammalian target of rapamycin (mTOR), more effective inhibition might be expected by targeting both PI3K and mTOR inhibition. MATERIALS AND METHODS: We investigated the effect of two dual PI3K/mTOR (both mTORC1 and mTORC2) inhibitors, NVP-BEZ235 and NVP-BGT226, on SQ20B laryngeal and FaDu hypopharyngeal cancer cells characterised by EGFR overexpression, on T24 bladder tumor cell lines with H-Ras mutation and on endothelial cells. Analysis of target protein phosphorylation, clonogenic survival, number of residual γH2AX foci, cell cycle and apoptosis after radiation was performed in both tumor and endothelial cells. In vitro angiogenesis assays were conducted as well. RESULTS: Both compounds effectively inhibited phosphorylation of Akt, mTOR and S6 target proteins and reduced clonogenic survival in irradiated tumor cells. Persistence of DNA damage, as evidenced by increased number of γH2AX foci, was detected after irradiation in the presence of PI3K/mTOR inhibition, together with enhanced G2 cell cycle delay. Treatment with one of the inhibitors, NVP-BEZ235, also resulted in decreased clonogenicity after irradiation of tumor cells under hypoxic conditions. In addition, NVP-BEZ235 blocked VEGF- and IR-induced Akt phosphorylation and increased radiation killing in human umbilical venous endothelial cells (HUVEC) and human dermal microvascular dermal cells (HDMVC). NVP-BEZ235 inhibited VEGF-induced cell migration and capillary tube formation in vitro and enhanced the antivascular effect of irradiation. Treatment with NVP-BEZ235 moderately increased apoptosis in SQ20B and HUVEC cells but not in FaDu cells, and increased necrosis in both tumor and endothelial all cells tumor. CONCLUSIONS: The results of this study demonstrate that PI3K/mTOR inhibitors can enhance radiation-induced killing in tumor and endothelial cells and may be of benefit when combined with radiotherapy. BioMed Central 2012-03-27 /pmc/articles/PMC3348043/ /pubmed/22452803 http://dx.doi.org/10.1186/1748-717X-7-48 Text en Copyright ©2012 Fokas et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Fokas, Emmanouil
Yoshimura, Michio
Prevo, Remko
Higgins, Geoff
Hackl, Wolfgang
Maira, Sauveur-Michel
Bernhard, Eric J
McKenna, W Gillies
Muschel, Ruth J
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
title NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
title_full NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
title_fullStr NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
title_full_unstemmed NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
title_short NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
title_sort nvp-bez235 and nvp-bgt226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348043/
https://www.ncbi.nlm.nih.gov/pubmed/22452803
http://dx.doi.org/10.1186/1748-717X-7-48
work_keys_str_mv AT fokasemmanouil nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT yoshimuramichio nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT prevoremko nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT higginsgeoff nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT hacklwolfgang nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT mairasauveurmichel nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT bernhardericj nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT mckennawgillies nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity
AT muschelruthj nvpbez235andnvpbgt226dualphosphatidylinositol3kinasemammaliantargetofrapamycininhibitorsenhancetumorandendothelialcellradiosensitivity